The Hepatitis C Global Market Report 2023, provides comprehensive information on the hepatitis c market across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.
Learn More On The Hepatitis C Market’s Growth:
https://thebusinessresearchcompany.com/report/hepatitis-c-global-market-report
As per The Business Research Company’s Hepatitis C Global Market Report 2023, the global hepatitis C market is expected to grow from $51.97 billion in 2022 to $59.58 billion in 2023 at a compound annual growth rate (CAGR) of 14.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and resulted in increased interest rates affecting many markets across the globe. The hepatitis C market is expected to reach $101.84 billion in 2027 at a CAGR of 14.3%.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=12582&type=smp
Advances in diagnostic technologies for hepatitis C are a key trend gaining popularity in the hepatitis C market. Major companies operating in the hepatitis C market are adopting new technologies to sustain their position in the market. For instance, in July 2022, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical and diagnostics company, launched Elecsys HCV Duo immunoassay in countries that accept the CE Mark. The hepatitis C virus (HCV) antigen and antibody status can now be determined independently and simultaneously from a single human plasma or serum sample using the immunoassay Elecsys HCV Duo. The test can identify patients recovering or exhibiting symptoms of a chronic infection that may result in other diseases, such as liver cancer and early-stage conditions.
The hepatitis c market is segmented:
1) By Type: Chronic Hepatitis C, Acute Hepatitis C, Other Types
2) By Treatment: Antiviral Drugs, Vaccine, Immune Modulator Drugs, Surgery, Other Treatments
3) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis
4) By Distribution Channel: Hospital And Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Laboratories, Research Institutes, Home Care Settings
North America was the largest region in the hepatitis c market in 2022.
Major players:
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- F. Hoffman La Roche Ltd.
- Merck & Co. Inc.
- AbbVie Inc.
- Bayer AG
The table of contents in TBRC’s hepatitis c market report includes:
1. Executive Summary
2. Hepatitis C Market Characteristics
3. Hepatitis C Market Trends And Strategies
4. Hepatitis C Market - Macro Economic Scenario
5. Global Hepatitis C Market Size and Growth
.
.
.
31. Hepatitis C Market Other Major And Innovative Companies
32. Global Hepatitis C Market Competitive Benchmarking
33. Global Hepatitis C Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Hepatitis C Market
35. Hepatitis C Market Future Outlook and Potential Analysis
36. Appendix
Related Reports:
https://goodprnews.com/green-coffee-market-forecast/
https://topprnews.com/oil-and-gas-market-forecast/
https://topprnews.com/military-night-vision-device-market-forecast/
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Non-Small Cell Lung Cancer Market is Expected to Increase With a CAGR of 10.7% for the Study Period of 2017-2030: DelveInsight (Albany, US) DelveInsight has introduced a new Market Insights, Epidemiology, and Market Forecast Report on "Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2030" to its portfolio.Key Highlights from report are:As per the DelveInsight analysis, the total incident cases of NSCLC in the 7MM were observed to be 484,726 cases in the year 2017.
These cases are expected to grow with a significant CAGR in the study period 2017–2030.There are different types of treatment available for NSCLC; however, mainly 10 types of standard treatment are used, which include Surgery, Radiation therapy, Chemotherapy, Targeted therapy, Immunotherapy, Laser therapy, Photodynamic therapy (PDT), Cryosurgery, Electrocautery, and Watchful waiting.The market size of NSCLC in the 7MM is expected to increase during study period.
According to the estimates, the highest contribution in the market size of NSCLC is from the United States followed by Japan, Germany, and the UK.One of the most exciting developments in lung cancer medicine is the introduction of targeted treatments.Request for free sample pages to know more on Non-Small Cell Lung Cancer Market Forecast NSCLC is the most common type of lung cancer accounted for approximately 85% of all lung cancers.
The disease epidemiology included in the report provides historical as well as forecasted Non-Small Cell Lung Cancer epidemiology, which is segmented as Total Incident cases of NSCLC patients, Total Incident cases of NSCLC patients by Histology, Total Diagnosed cases of NSCLC patients by Stages, Total NSCLC cases of patients by Genetic mutation/Biomarkers, and Total Treated Cases of NSCLC patients by Line of Therapies scenario of NSCLC in the 7MM.The total NSCLC incident cases in the 7MM were observed to be 484,726 cases in 2017.Click here to know more on Non-Small Cell Lung Cancer pipelineNSCLC report encloses the detailed analysis of Non-Small Cell Lung Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.
The therapies that are approved for the NSCLC treatment are Rozlytrek (Entrectinib), Imfinzi (Durvalumab), Opdivo (Nivolumab), Tecentriq (Atezolizumab), Keytruda (Pembrolizumab), Tafinlar (Dabrafenib) in combination with Mekinist (Trametinib), Tagrisso (osimertinib), Lorbrena/Lorviqua (Lorlatinib), Vizimpro (Dacomitinib), Alunbrig (Brigatinib), Alecensa (Alectinib), Vitrakvi (Larotrectinib), Portrazza (Necitumumab) along with many more.Drugs covered in the report are:-There are several key players robustly involved in developing potential products such asNazartinib (EGF816)Capmatinib (INC280)Tepmetko (tepotinib)MerestinibJNJ-61186372 (JNJ-6372)Vemurafenib Plus CobimetinibX-396 (Ensartinib)Tedopi (OSE2101)Selpercatinib (LY3527723/ LOXO-292)SAR408701Braftovi (encorafinib) + Mektovi (binimetinib)PADCEV (enfortumab vedotin/ASG-22ME)Pralsetinib (BLU-667)TAK-788: Canakinumab (ACZ885)Avelumab (Bavencio)Veliparib (ABT-888): Sitravatinib (MGCD516)TesevatinibRomiplostim: CabozantinibSym015AMG 510INCMGA00012 (MGA012)Libtayo (Cemiplimab)BavituximabM7824 (Bintrafusp alfa)And many others Key Players covered in the report are:-Novartis PharmaceuticalsMerck KGaAEli Lilly and CompanyJanssen Research & DevelopmentHoffmann-La RocheXcoveryBeyondSpring PharmaceuticalsOSE ImmunotherapeuticsSanofiPfizerAstellas PharmaSeattle GeneticsBlueprint Medicines CorporationTakedaAbbVieKadmon CorporationAmgenSymphogenRegeneron PharmaceuticalsPeregrine PharmaceuticalsAvid BioservicesGlaxoSmithKlineAnd many othersThe report includes provides in depth analysis historical and forecasted Market Share (%) Distribution of NSCLC, Market Share (%) Distribution of NSCLC by Mutations/Biomarkers, Total Market Size of PD-L1 NSCLC, Total Market Size of BRAF NSCLC, Total Market Size of c-Met, Total Market Size of EGFR, Total Market Size of ALK as well.The reasons for buying this report:The report proffers an overview of pathophysiology, various diagnostic approaches and NSCLC treatment algorithm, including detailed chapters for marketed products and emerging therapies.Historical and forecasted Non-Small Cell Lung Cancer epidemiology in 7MM covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017-2030.Detailed historical and forecasted NSCLC market covering the United States, EU5 and Japan from 2017-2030.
Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with comprehensive clinical profiles, key cross-competition, launch date along with product development activities.
Global Hepatitis C Treatment Market: OverviewThe demand within the global market for hepatitis C treatment has been rising on account of advancements in the field of healthcare and medicine.
Several new treatment lines for the treatment of hepatitis C have been developed over the past decade.
Henceforth, the global market for hepatitis C treatment has accumulated voluminous revenues over the past decade.
Healthcare professionals have emphasised on the need to develop new treatment lines for hepatitis C. There is no doubt about the fact that the global hepatitis C treatment would accumulate humongous revenues in the years to come.
The emergence of new vendors in the global hepatitis C treatment has also aided market growth.Strong expertise with attention to detail makes our market research reports stand apart, Request a Report sample @https://www.transparencymarketresearch.com/sample/sample.php?flag=S_id=65471The global hepatitis C treatment has been segmented on the basis of the following parameters: treatment type, end user, and region.
Furthermore, new entries have invested in the global hepatitis C treatment market which has in turn given an impetus to the growth of the global market.Request COVID Analysis on Hepatitis C Market –https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=65471Global Hepatitis C Treatment Market: Regional OutlookOn the basis of geography, the global market for hepatitis C treatment can be segmented into Latin America, North America, the Middle East and Africa, Europe, and Asia Pacific.